Khiron Life Sciences Corp
Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and s… Read more
Khiron Life Sciences Corp (KHRNF) - Total Liabilities
Latest total liabilities as of September 2022: $11.35 Million USD
Based on the latest financial reports, Khiron Life Sciences Corp (KHRNF) has total liabilities worth $11.35 Million USD as of September 2022.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Khiron Life Sciences Corp - Total Liabilities Trend (2011–2021)
This chart illustrates how Khiron Life Sciences Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Khiron Life Sciences Corp Competitors by Total Liabilities
The table below lists competitors of Khiron Life Sciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liontrust Asset Management
LSE:LIO
|
UK | GBX157.94 Million |
|
Fonix Mobile plc
LSE:FNX
|
UK | GBX47.45 Million |
|
EUTELSAT COMM.
MU:E3B
|
Germany | €4.57 Billion |
|
Notoria
WAR:NTS
|
Poland | zł1.01 Million |
|
Eckoh Plc
LSE:ECK
|
UK | GBX12.93 Million |
|
Pressure Biosciences Inc
OTCQB:PBIO
|
USA | $44.11 Million |
|
BHB BRAUHOLDING
MU:B9B
|
Germany | €3.50 Million |
|
Gamer Pakistan Inc. Common Stock
PINK:GPAK
|
USA | $38.96K |
Liability Composition Analysis (2011–2021)
This chart breaks down Khiron Life Sciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.42 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Khiron Life Sciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Khiron Life Sciences Corp (2011–2021)
The table below shows the annual total liabilities of Khiron Life Sciences Corp from 2011 to 2021.
| Year | Total Liabilities | Change |
|---|---|---|
| 2021-12-31 | $8.95 Million | -10.10% |
| 2020-12-31 | $9.95 Million | -16.20% |
| 2019-12-31 | $11.87 Million | -19.84% |
| 2018-12-31 | $14.81 Million | +117245.97% |
| 2017-12-31 | $12.62K | -89.25% |
| 2016-12-31 | $117.37K | +13.27% |
| 2015-12-31 | $103.62K | +243.81% |
| 2014-12-31 | $30.14K | -66.65% |
| 2013-12-31 | $90.39K | +170.67% |
| 2012-12-31 | $33.39K | +27.40% |
| 2011-12-31 | $26.21K | -- |